Atara Biotherapeutics Announces $36 Million Registered Direct Offering
03 Septiembre 2024 - 3:16PM
Business Wire
Led by Existing Top Institutional Investors
With Participation From a New Strategic Investor
Well Positioned To Execute on Tab-cel® U.S. BLA
Approval and Advancement of ATA3219
Further Strengthens Balance Sheet With Cash
Runway Into 2027 Enabling Key Pipeline Readouts
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell
immunotherapy, leveraging its novel allogeneic Epstein-Barr virus
(EBV) T-cell platform to develop transformative therapies for
patients with cancer and autoimmune diseases, today announced that
it has entered into definitive agreements for the issuance and sale
of 758,900 shares of its common stock at a purchase price of $8.25
per share and the issuance and sale of pre-funded warrants to
purchase up to 3,604,780 shares of its common stock at a purchase
price of $8.2499 per share in a registered direct offering,
representing a premium of 15% to Atara’s 7-day volume-weighted
average price, to entities affiliated with Redmile Group, EcoR1
Capital, and Adiumentum Capital Management, as well as a strategic
investment from a large public biotechnology company. The
pre-funded warrants will have an exercise price of $0.0001 per
share and will be immediately exercisable upon issuance. The
offering is expected to close on or about September 5, 2024,
subject to the satisfaction of customary closing conditions.
In connection with the offering, Greg Ciongoli, founder and
managing partner of Adiumentum Capital Management, will join
Atara’s Board of Directors.
“Atara’s innovative cell therapies, like tab-cel and its
differentiated allogeneic CAR-T portfolio, have the potential to
transform the lives of cancer and autoimmune patients,” said Greg
Ciongoli. “With the prospective U.S. approval for tab-cel and
several anticipated CAR-T data readouts all approaching, this is an
exciting time to join Atara’s Board and to partner with its strong
leadership team.”
“We are very pleased to have Greg join our Board, and I look
forward to collaborating with him as I transition to Chairman,”
said Pascal Touchon, President and Chief Executive Officer. “He has
over two decades of investing experience and deep industry
knowledge, which will complement our Board of Directors well.”
The gross proceeds to Atara from the offering are expected to be
$36 million, before deducting estimated offering expenses payable
by Atara. Atara currently intends to use the net proceeds from the
offering for working capital and general corporate purposes.
The securities described above are being offered by Atara
pursuant to a shelf registration statement on Form S-3 (No.
333-275256), including a base prospectus, that was previously filed
by Atara with the U.S. Securities and Exchange Commission (the
“SEC”) and was declared effective on November 13, 2023. A
prospectus supplement containing additional information relating to
the offering will be filed with the SEC and will be available on
the SEC’s website located at http://www.sec.gov.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of
these securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to the registration or
qualification under the securities laws of any such state or
jurisdiction.
About Atara Biotherapeutics, Inc.
Atara is harnessing the natural power of the immune system to
develop off-the-shelf cell therapies for difficult-to-treat cancers
and autoimmune conditions that can be rapidly delivered to patients
from inventory. With cutting-edge science and differentiated
approach, Atara is the first company in the world to receive
regulatory approval of an allogeneic T-cell immunotherapy. Atara’s
advanced and versatile T-cell platform does not require T-cell
receptor or HLA gene editing and forms the basis of a diverse
portfolio of investigational therapies that target EBV, the root
cause of certain diseases, in addition to next-generation
AlloCAR-Ts designed for best-in-class opportunities across a broad
range of hematological malignancies and B-cell driven autoimmune
diseases. Atara is headquartered in Southern California.
Forward-Looking Statements
This press release contains or may imply “forward-looking
statements” within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended. For example, forward-looking statements
include statements regarding the completion, timing and size of the
offering and the anticipated use of proceeds of the offering and
Mr. Ciongoli’s service on the Company’s board of directors. Because
such statements deal with future events and are based on Atara’s
current expectations, they are subject to various risks and
uncertainties and actual results, performance or achievements of
Atara could differ materially from those described in or implied by
the statements in this press release. These forward-looking
statements are subject to risks and uncertainties, including
without limitation risks and uncertainties related to market
conditions and satisfaction of customary closing conditions related
to the offering, as well as those discussed in Atara’s filings with
the SEC, including in the “Risk Factors” and “Management’s
Discussion and Analysis of Financial Condition and Results of
Operations” sections of the prospectus supplement and Atara’s most
recently filed periodic reports on Form 10-K and Form 10-Q and
subsequent filings and in the documents incorporated by reference
therein. Except as otherwise required by law, Atara disclaims any
intention or obligation to update or revise any forward-looking
statements, which speak only as of the date hereof, whether as a
result of new information, future events or circumstances or
otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240903938497/en/
Investor and Media Relations: Jason Awe, Ph.D. Head of
Corporate Communications & Investor Relations (805) 217-2287
jawe@atarabio.com
Atara Biotherapeutics (NASDAQ:ATRA)
Gráfica de Acción Histórica
De Sep 2024 a Oct 2024
Atara Biotherapeutics (NASDAQ:ATRA)
Gráfica de Acción Histórica
De Oct 2023 a Oct 2024